Question · asked by 1 review
Short‐acting insulin analogues vs regular human insulin: Adverse events other than severe hypoglycaemic episodes (all non‐severe hypoglycaemic episodes) (Events per participant per month)
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Short‐acting insulin analogues vs regular human insulin Adverse events other than severe hypoglycaemic episodes (all non‐severe hypoglycaemic episodes) (Events per participant per month) Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2… (2018) · Cochrane Headline outcomes only | no estimate extracted | 7 studies · 2667 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes mellitus 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.